Joe Keegan, Former CEO of Octet-Manufacturer ForteBio, Joins Nanomedical Diagnostics Board of Directors

Share Article

Dr. Keegan to provide expertise in the label-free detection market as the company expands sales of AGILE R100, its benchtop biosensor assay for lead optimization.

Joe Keegan, former CEO of ForteBio, to join Nanomedical Diagnostics Board of Directors

Dr. Joe Keegan to join Nanomedical Diagnostics Board of Directors

AGILE has the ability to be disruptive in the label-free analysis market and make a transformative impact on life science research.

Nanomedical Diagnostics, a biotech company driving the use of label-free biosensor assays in life science research and diagnostics, appoints Dr. Joe Keegan to its Board of Directors. With over thirty years of experience working with cutting-edge, novel technologies, Dr. Keegan has a proven track record of developing early stage companies into successes in the life science market. Notably, Dr. Keegan led ForteBio, Inc., manufacturer of the Octet and Blitz lines of label-free detection systems, from $6MM in revenue in 2007 to $27MM in 2011, the year prior to its acquisition by Pall Life Sciences. Dr. Keegan also served as CEO of Molecular Devices Corporation from 1998 to 2007 where he grew revenue from $30MM to $185MM.

“We are thrilled to welcome Joe Keegan to our board and look forward to the wealth of proven business and technology experience he brings as we expand sales,” says Nanomedical Diagnostics CEO, Ross Bundy. “AGILE R100 is based on game-changing technology with all the inherent challenges introducing a novel method brings. Dr. Keegan has demonstrated success in this area and will be an indispensable guide as we move forward.”

AGILE R100 is a benchtop label-free assay that provides sensitive real-time binding kinetics and concentration data for optimizing lead compounds during drug discovery. Built with Field Effect Biosensing (FEB) technology, the all-electronic platform can detect small molecules and fragments with no lower size limit in up to 10% DMSO in as little as 10 µL.

“I recognized immediately that AGILE has the ability to be disruptive in the label-free analysis market,” says Dr. Keegan. “I’ve been impressed with the co-founders’ thoughtful approach to the growth of the company and am delighted to join the talented members of the board as Nanomedical Diagnostics begins the journey of making a transformative impact on life science research."

Dr. Keegan currently serves on the Boards of Directors of Courtagen Life Sciences, Interpace Diagnostics Inc., Labcyte Corporation as Chairman, Optofluidics, Inc., Response Biomedical Corporation, Unchained Labs, Inc., Wasatch Microfluidics, Inc., and the San Francisco Opera. He joins Nina Saberi, Tim Hoerr, Brett Goldsmith, and Ross Bundy on the Nanomedical Diagnostics Board of Directors.

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a biotech company based in San Diego, CA. Nanomed has developed a breakthrough all-electronic assay based on Field Effect Biosensing (FEB) technology that provides real-time, label-free kinetic binding and concentration data. AGILE biosensor chips at the heart of the assay leverage the highly sensitive nanomaterial graphene to unite biology with electronics, delivering the unique ability to sense small molecules with no lower size limit in complex media such as DMSO, and use unprecedentedly small amounts of sample.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Visit website